Related Experiment Video
Updated: Nov 6, 2025
07:27
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
24.9K
Flecainide toxicity late after liver transplantation
Ossama Elsaid1, Kristen M Tecson2,3, Hafiza Khan4
1Division of Cardiology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.
Proceedings (Baylor University. Medical Center)
|May 6, 2021
Summary
Flecainide toxicity, a rare but serious condition, can occur in patients with supraventricular arrhythmias. This case highlights flecainide toxicity in a patient with both kidney and liver failure, emphasizing the need for careful monitoring.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Flecainide is an antiarrhythmic medication used for supraventricular arrhythmias.
- It is contraindicated in patients with structural heart disease or ischemic heart disease.
- Flecainide toxicity is a rare but potentially fatal condition.
Observation:
- The case involves a patient who developed flecainide toxicity.
- The patient had co-existing renal and liver failure.
- Symptoms of toxicity included bradycardia, QRS widening, and ventricular tachycardia.
Findings:
- Flecainide toxicity presents with various cardiac and systemic symptoms.
- Renal and liver failure can exacerbate or precipitate flecainide toxicity.
- The mortality rate associated with flecainide toxicity is approximately 10%.
Implications:
- This case underscores the importance of considering organ function in flecainide use.
- Careful patient selection and monitoring are crucial to prevent toxicity.
- Further research may be needed to establish specific guidelines for flecainide use in patients with organ dysfunction.
More Related Videos
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
56
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
56
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
65
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
65
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
47
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
47
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.5K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.5K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
57
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
57